<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00410137</url>
  </required_header>
  <id_info>
    <org_study_id>43/06</org_study_id>
    <nct_id>NCT00410137</nct_id>
  </id_info>
  <brief_title>Influence of Nutritional and Inflammational Status on Survival of Hemodialysis Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <brief_summary>
    <textblock>
      prospective longitudinal measurements of nutritional status parameters (body composition by&#xD;
      BIA, anthropometry and biochemical indexes), inflammatory response (CRP, inflammatory&#xD;
      cytokines (IL-1, IL-6, IL-10),IGF-1, leptin and NOx blood levels) and morbidity and mortality&#xD;
      data collection over 2 year period in patients receiving chronic hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <completion_date>April 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>100</enrollment>
  <condition>Inflammation</condition>
  <condition>Body Composition</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age &gt; 18 years, in chronic hemodialysis treatment at least 3 months&#xD;
&#xD;
          -  Stable and adequate hemodialysis treatment three months prior to participation in&#xD;
             study as defined by Kt/V &gt; 1.2 and/or hemodialysis performed 4 hours 3 times weekly&#xD;
&#xD;
          -  Patients with normal hydration status (edema-free), with no neuro-muscular diseases&#xD;
&#xD;
          -  Informed consent obtained before any trial-related activities&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with edema, pleural effusion or ascites at their initial assessment&#xD;
&#xD;
          -  Patients with active malignant disease or liver cirrhosis&#xD;
&#xD;
          -  Patients with neuro-muscular diseases&#xD;
&#xD;
          -  Patients on chronic treatment with steroids on doses &gt; 10 mg/day Prednisone (or&#xD;
             equivalent)&#xD;
&#xD;
          -  Patients treated with immunosuppressive agents&#xD;
&#xD;
          -  Patients suffering from&#xD;
&#xD;
               -  Acute vasculitis&#xD;
&#xD;
               -  Severe systemic infections&#xD;
&#xD;
               -  Heart failure (NYHA class III-IV)&#xD;
&#xD;
          -  The receipt of any investigational drug within 1 month prior to initiating of this&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilia Beberashvili, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilia Beberashvili, MD</last_name>
      <phone>+972577346133</phone>
      <email>iliab@asaf.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ilia Beberashvili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>December 10, 2006</study_first_submitted>
  <study_first_submitted_qc>December 11, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2006</study_first_posted>
  <last_update_submitted>December 11, 2006</last_update_submitted>
  <last_update_submitted_qc>December 11, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

